The estimated Net Worth of James F. Reddoch is at least 65.4 百万$ dollars as of 28 September 2022. Dr Reddoch owns over 100,000 units of Royalty Pharma plc stock worth over 22,801,824$ and over the last 4 years he sold RPRX stock worth over 39,247,147$. In addition, he makes 3,395,000$ as Exec. VP、 Chief Scientific Officer and Co-Head of Research & Investments at Royalty Pharma plc.
Dr has made over 14 trades of the Royalty Pharma plc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 100,000 units of RPRX stock worth 4,123,000$ on 28 September 2022.
The largest trade he's ever made was selling 200,000 units of Royalty Pharma plc stock on 4 June 2021 worth over 9,110,000$. On average, Dr trades about 50,497 units every 32 days since 2020. As of 28 September 2022 he still owns at least 820,800 units of Royalty Pharma plc stock.
You can see the complete history of Dr Reddoch stock trades at the bottom of the page.
Dr. James Folmar Reddoch Ph.D. is the Exec. VP, Chief Scientific Officer and Co-Head of Research & Investments at Royalty Pharma plc.
As the Exec. VP、 Chief Scientific Officer and Co-Head of Research & Investments of Royalty Pharma plc, the total compensation of Dr D at Royalty Pharma plc is 3,395,000$. There are 2 executives at Royalty Pharma plc getting paid more, with Pablo Gerardo Legorreta having the highest compensation of 55,674,558$.
Dr D is 51, he's been the Exec. VP、 Chief Scientific Officer and Co-Head of Research & Investments of Royalty Pharma plc since . There are 3 older and no younger executives at Royalty Pharma plc. The oldest executive at Royalty Pharma plc is George Wingate Lloyd, 62, who is the Exec. VP of Investments & Gen. Counsel.
James's mailing address filed with the SEC is C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK, NY, 10022.
Over the last 4 years, insiders at Royalty Pharma plc have traded over 863,995,127$ worth of Royalty Pharma plc stock and bought 5,330,350 units worth 152,553,456$ . The most active insiders traders include David C Hodgson、William E Ford、Capital Partners Gp, L.L.C..... On average, Royalty Pharma plc executives and independent directors trade stock every 13 days with the average trade being worth of 7,420,205$. The most recent stock trade was executed by Rory B Riggs on 2 January 2024, trading 470,000 units of RPRX stock currently worth 13,221,100$.
royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi
Royalty Pharma plc executives and other stock owners filed with the SEC include: